Phase 2 of Neovasc's TIARA-II Study to Commence in Germany and the United Kingdom
January 29, 2019—Neovasc Inc. announced that it has completed the phase 1 requirements of the TIARA-II study required by the biphasic study design in both Germany and the United Kingdom. The company has received approval to proceed with phase 2 of the TIARA-II study for its Tiara transcatheter mitral valve replacement device. The approval will allow the TIARA-II study to proceed in these geographies with no restrictions.
According to the company, this approval comes after adjudication of adverse events by the Clinical Events Committee as well as Data and Safety Monitoring Board review of the data, and governmental regulatory and ethics committee reviews of the interim clinical report provided for 20 patients receiving implants.
The TIARA-II study is an international, multicenter, single-arm, prospective, nonrandomized, safety and performance clinical study. The total enrollment goal for the study in all geographies is 115 implanted subjects.
Tiara is a self-expanding mitral bioprosthesis designed to treat mitral valve regurgitation by replacing the diseased valve. The Tiara valve is currently being evaluated in the TIARA I early feasibility trial in the United States, Canada, and Belgium, and in the TIARA II European CE Mark trial in Germany, Italy, and the United Kingdom.
advertisement
Featured Video
Evolut™ PRO System
Sponsored by Medtronic
Related Articles
Catheter-Based Tricuspid Intervention
A review of current leaflet, annular, and valve replacement device technologies.
By Abdellaziz Dahou, MD, PhD; Juan F. Granada, MD; and Rebecca T. Hahn, MD
Echocardiographic Imaging in Transcatheter Mitral and Tricuspid Valve Therapies
Essential tips, challenges, and future perspectives in imaging for transcatheter valve therapies.
By Osama Soliman, MD, PhD, FACC, FESC; Chun Chin Chang, MD; and Thomas Modine, MD, PhD, MBA
Top 5 Articles From October 2018
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
By Ginger Biesbrock, PA-C, MPH, MPAS, AACC; and Joel Sauer, MBA
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Planning for Transcatheter Aortic Valve Replacement
By Moderator: Mauricio G. Cohen, MD, FACC, FSCAI
Panel: Santiago Garcia, MD, FACC, FSCAI; William O’Neill, MD; and Molly Szerlip, MD, FACC, FSCAI
Top 5 from EVToday's Current Issue
Roundtable Discussion: Percutaneous AVF Creation in Practice
A multidisciplinary discussion on patient selection, achieving proficiency, procedural tips, and the importance of collaboration.
With John E. Aruny, MD; William C. Jennings, MD, FACS; Charmaine E. Lok, MD; and Aris Urbanes, MD
Understanding Benefits and Risks of Drug-Eluting Stents
Ongoing clinical studies will shed light on patient outcomes in real-world settings.
By Ian T. Meredith, MBBS, PhD, AM
Evaluation and Management of Chronic Thoracic Venous Obstructions
Clinical presentation, anatomic patterns of TCVO, and revascularization strategies.
By Brian Holly, MD; and Mark L. Lessne, MD
AV Access Covered Stent Clinical Trials: A Comparative Review
A status overview of six major clinical trials evaluating the use of covered stents in AV access treatment.
